EGFR and non-small cell lung carcinoma: Indeed, it has been recently reported that the administration of Osimertinib in the context of adjuvant treatment in resected EGFR mutant NSCLC significantly reduced the relapse rate and prolonged the overall survival (Wu et al., 2020).